Releases

23/05/25

Weekly information on the purchase of treasury shares

16/05/25

Weekly information on the purchase of treasury shares

14/05/25

SVAS Biosana will participate in TP ICAP MIDCAP

09/05/25

The Board of Directors examines consolidated revenues as of 31/03/2025

09/05/25

Weekly information on the purchase of treasury shares

05/05/25

Notice of Ordinary Shareholders’ Meeting

02/05/25

Weekly information on the purchase of treasury shares

25/04/25

Weekly information on the purchase of treasury shares

23/04/25

The Board of Directors approves the financial statements as of 12/31/2024

17/04/25

Weekly information on the purchase of treasury shares

15/04/25

The Board of Directors approves the financial statements as of 12/31/2024

12/04/25

Weekly information on the purchase of treasury shares

04/04/25

Weekly information on the purchase of treasury shares

31/03/25

SVAS Biosana takes part in the Spring Investor Conference

28/03/25

Weekly information on the purchase of treasury shares

21/03/25

Weekly information on the purchase of treasury shares

14/03/25

Weekly information on the purchase of treasury shares

10/03/25

SVAS Biosana announces the completion of the acquisition of Hermes Pharma D.O.O. and Megapharm D.O.O.

07/03/25

Weekly information on the purchase of treasury shares

28/02/25

Weekly information on the purchase of treasury shares

21/02/25

Weekly information on the purchase of treasury shares

14/02/25

Weekly information on the purchase of treasury shares

14/02/25

Board of Directors examines consolidated revenues as of 12/31/2024

07/02/25

Weekly information on the purchase of treasury shares

31/01/25

Weekly information on the purchase of treasury shares

30/01/25

Svas Biosana – Financial calendar 2025 approved

30/12/24

Signed Agreement for Acquisition of Megapharm D.o.o.

27/12/24

SVAS Biosana – Ordinary and Extraordinary Assembly and Board of Directors 27.12.2024

23/12/24

SVAS Biosana – Signing of Agreement for Acquisition of Hermes Pharma D.o.o.

12/12/24

SVAS Biosana – Notice of Shareholders’ Meeting 27.12.2024

11/12/24

Weekly information on the purchase of treasury shares

15/11/24

Weekly information on the purchase of treasury shares

15/11/24

Weekly information on the purchase of treasury shares

08/11/24

Weekly information on the purchase of treasury shares

08/11/24

The Board of Directors examines consolidated revenues as of 09.30.2024

01/11/24

Weekly information on the purchase of treasury shares

25/10/24

Weekly information on the purchase of treasury shares

21/10/24

Management of SVAS Biosana participates in the fifth edition of the Next Gems Conference

18/10/24

Weekly information on the purchase of treasury shares

18/10/24

SVAS Biosana approves a bond issue for a total value of Euro six million

11/10/24

Weekly information on the purchase of treasury shares

04/10/24

Weekly information on the purchase of treasury shares

27/09/24

Weekly information on the purchase of treasury shares

26/09/24

The Board Of Directors Of SVAS BIOSANA approves the half-yearly consolidated financial statements as of 30 June 2024

20/09/24

Weekly information on the purchase of treasury shares

13/09/24

Weekly information on the purchase of treasury shares

11/09/24

Svas Biosana takes part in the Autumn Investor Conference Event

06/09/24

Weekly information on the purchase of treasury shares

30/08/24

Weekly information on the purchase of treasury shares

02/08/24

Consolidated Revenues At 30 June 2024

02/08/24

Weekly information on the purchase of treasury shares

31/07/24

SVAS Biosana – Closing of the 3rd warrant period 2021-2024

26/07/24

Weekly information on the purchase of treasury shares

19/07/24

Weekly information on the purchase of treasury shares

12/07/24

Weekly information on the purchase of treasury shares

05/07/24

Weekly information on the purchase of treasury shares

03/07/24

Material change of significant shareholders

15/05/24

Financial Statements at 31 December 2023 approved

17/04/24

Preliminary Financial Statements and Consolidated Financial Statements at 31 December 2023

09/11/23

Consolidated Revenues At 30 September 2023

27/09/23

The Board of Directors of SVAS Biosana approves the short-form consolidated half-yearly financial statements as at 30 june 2023

04/08/23

The Board of Directors of SVAS Biosana examines the consolidated turnover as at 30 june 2023

01/08/23

Chiusura del secondo periodo di esercizio dei warrant SVAS Biosana 2021-2024

30/06/23

Beginning of the second exercise period for SVAS Biosana

16/05/23

Financial statements as at and for the year ended 31 December 2022 approved

09/05/23

Approval of consolidated revenues Q1 2023

14/04/23

Approval of the financial statements at 31 December 2022

13/02/23

SVAS unveils its preliminary consolidated turnover for 2022

09/11/22

The board of directors of SVAS Biosana consolidated turnover for the third quarter of 2022

26/09/22

The board of directors approves the consolidated half-yearly financial report as at 30.06.2022

05/08/22

SVAS growth trend accelerates

29/07/22

2021-2024 SVAS Biosana Warrants

29/06/22

Warrants SVAS Biosana 2021-2024

28/06/22

MID Small Virtual

23/06/22

Bormia closing transaction

23/05/22

Euronext Growth Conference

17/05/22

SVAS Biosana acquires the “BORMIA” group which distributes high-quality medical devices in Slovenia and Croatia

16/05/22

SVAS Biosana S.p.A.’s ordinary shareholders’ meeting

15/04/22

The board of directors of SVAS Biosana approves the draft for the year ended 31 december 2021

14/02/22

Preliminary consolidated turnover 2021

28/01/22

SVAS Biosana publishes its financial calendar for 2022

07/01/22

SVAS Biosana: Greenshoe option

09/12/21

Successful debut on EURONEXT GROWTH MILAN market for SVAS Biosana

09/12/21

Notified to CONSOB the KID “KEY INFORMATION DOCUMENT” relating to the “SVAS BIOSANA WARRANTS 2021-2024”